| Identification | Back Directory | [Name]
ABX-464 | [CAS]
1258453-75-6 | [Synonyms]
ABX-464
ABX464(ABX-464
2-Quinolinamine, 8-chloro-N-[4-(trifluoromethoxy)phenyl]- | [EINECS(EC#)]
824-937-7 | [Molecular Formula]
C16H10ClF3N2O | [MDL Number]
MFCD31657325 | [MOL File]
1258453-75-6.mol | [Molecular Weight]
338.71 |
| Chemical Properties | Back Directory | [Boiling point ]
412.3±45.0 °C(Predicted) | [density ]
1.440±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : ≥ 100 mg/mL (295.24 mM) | [form ]
Solid | [pka]
1.50±0.61(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Obefazimod (ABX464) is a potent anti-HIV agent. Obefazimod inhibits HIV-1 replication in stimulated peripheral blood mononuclear cells (PBMCs) with an IC50 ranging between 0.1 μM and 0.5 μM. | [in vivo]
Humanized mice reconstituted with human lymphoid cells provide rapid, reliable, reproducible experimental systems for testing the efficacy of Obefazimod in vivo. In the initial setting, SCID mice are reconstituted with PBMCs and then infected with the HIV-1 strain JR-CSF. Mice are treated twice a day (b.i.d) for 15 days by oral gavage with 20 mg/kg of Obefazimod. Measures of viral RNA show that the oral treatment with Obefazimod is able to significantly reduce the viral load over a period of 15 days of treatment. FACS analysis of blood samples show that treatment with Obefazimod prevents depletion of CD4+ cells following infection of reconstituted mice and thereby restores the CD8+/CD4+ ratio back to that of non-infected mice[1]. | [IC 50]
HIV-1: 0.1-0.5 μM (IC50, in PBMCs) | [storage]
Store at -20°C | [References]
[1] Campos N, et al. Long lasting control of viral rebound with a new drug ABX464 targeting Rev-mediated viral RNA biogenesis. Retrovirology. 2015 Apr 9;12:30. DOI:10.1186/s12977-015-0159-3 |
|
| Company Name: |
Twochem Co.Ltd.
|
| Telephone: |
021-58111628 15800915896 |
| Website: |
cn.twochem.com |
|